The Pfizer team (1) made use of the company's screening file, comprising some 1.6 million compounds. A significant number of these compounds were heterocycles designed to be ATP-competitive ligands for the ATP binding site of a eukaryotic protein kinase. They screened their library against a membrane-compromised (imp), efflux pump-deficient (tolC) strain of Escherichia coli to find molecules that entered and killed whole cells. Their choice of indicator strain imparted a focus on molecules with anti-Gram-negative activity from the outset.
Miller et al. (1) identified promising hits from a series of pyridopyrimidines and determined that drug-resistant mutants (1 in 10 9 ) mapped to the biotin carboxylase (BC) subunit of the multisubunit enzyme acetyl-CoA carboxylase, which catalyzes the first committed step in fatty acid biosynthesis (Fig. 1) . Intriguingly, the pseudopeptide natural product andrimid is a nanomolar inhibitor of the carboxyltransferase subunit of the same enzyme (3), raising the prospect of the synergistic action of 2 drugs against this essential enzyme.
Bacterial fatty acid biosynthesis has long been thought to be an underexploited pathway for antibiotics. Although 2 inhibitors of the enoylreductase component of fatty acid synthase (FAS) (isoniazid, used in combination therapies for tuberculosis, and triclosan, an antiseptic) have seen use in humans, no other clinically-used antibiotics target this pathway. However, recent efforts to identify inhibitors of fatty acid biosynthesis have yielded promising leads: a screen of natural product extracts at Merck turned up the Streptomyces metabolite platensimycin as a potent inhibitor of the FAS chain elongation enzyme (4) .
The BC subunit of acetyl-CoA carboxylase carries out this enzyme's first half-reaction: activating bicarbonate by cleaving ATP to ADP and transiently generating the mixed anhydride carboxyphosphate. This activated carboxyl moiety is then captured by biotin [which is tethered to the biotin carboxyl carrier protein (BCCP)], to yield N-carboxybiotinyl-BCCP (Fig. 1) . A second subunit, the carboxyltransferase, generates the thioester enolate of acetyl-CoA and catalyzes its attack on the biotin-tethered carboxyl group to generate malonylCoA, the building block for fatty acid synthesis. The BC subunit, which had been crystallized (5) , is a member of the ATP-grasp enzyme superfamily. The crystal structures of library compounds 1 and 2 in complex with the BC subunit confirmed that they bind to its ATPbinding site. Hit molecules from the screen were bactericidal against E. coli and the consequential Gram-negative respiratory pathogens Haemophilus influenzae and Moraxella catarrhalis, but not against Gram-positive bacteria. Compound 1 has a K d of 0.8 nM against the purified BC subunit from E. coli, and the selectivity profile of compounds 1 and 2 is encouraging: no significant inhibition of 30 eukaryotic protein kinases, including VEGFR-2 and FGFR-1, the targets for which these heterocyclic scaffolds had been optimized. Thus, the ATP-binding sites of eukaryotic and prokaryotic enzymes may be an expanding class of valuable targets for molecules with nanomolar potency and selectivity.
One of the ATP-binding site mutations in BC that conferred pyridopyrimidine resistance was I437T. BC subunits from Gram-positive bacteria harbor a threonine at this position, providing a possible explanation for why compounds 1 and 2 are selective for Gram-negative bacteria. Further examination of the library, leveraging the prior medicinal chemical investment by Pfizer in eukaryotic tyrosine kinase inhibitors, showed that compound 3, with a K d of 150 nM, was only 14-fold less potent against the I437T BC mutant. This result gives a clear path for future medicinal chemical efforts to tailor the pyridopyrimidine scaffold to get higher efficacy against BCs from Gram-positive pathogens such as S. aureus.
Initial pharmacokinetic studies in mice led to the demonstration of efficacy in both a thigh model and a systemic model of murine infection with H. influenzae. Anticipating that a BC inhibitor might be a candidate for combination therapy, compound 1 was tested for antagonism or synergy with a several antibiotics; the antiseptic triclosan and the DNA gyrase inhibitor ciprofloxacin were synergistic. Because andrimid inhibits the other catalytic subunit of acetyl-CoA carboxylase (Fig. 1) , it might be of interest to evaluate it in combination with the pyridopyrimidines for potential synergy.
In (1) suggest that rescreening with eukaryotic targetdirected ATP-mimetic libraries would be worthwhile. It is unclear how many ATP-using enzymes in the bacterial proteome, both phosphoryl transferases and adenylyl transferases, could be targeted by existing eukaryotic kinase libraries. However, it is promising that ATPmimetic scaffolds have been particularly malleable for exploring target protein selectivity while maintaining high potency.
Finally, the question arises whether a similar strategy of using synthetic chemical libraries developed and iteratively improved for other classes of eukaryotic proteins might be profitably screened against bacterial targets in whole-cell assays. Two target classes that might be worth particular attention are ion channels and prenyltransferases (9) .
